News

December 21, 2018

Bio-Thera Begins Phase 1 Trial of BAT4306F in Advanced B-cell Non-Hodgkin’s Lymphoma

News

Bio-Thera Solutions has started dosing patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma with its investigational therapy BAT4306F in a Phase 1 clinical trial. Taking place in China, the trial (ChiCTR1800018900) ... Read more

December 18, 2018

Depleting White Blood Cells Improves Response to CAR T-cell Therapy in Heavily Treated Patients, Trial Shows

News

A preconditioning chemotherapy regimen given before CD30.CAR-T therapy — a CAR T-cell therapy directed at CD30-positive cancers — seems to improve heavily treated lymphoma patients’ responses to the treatment, a Phase 1/2 ... Read more

December 17, 2018

Calquence Shows Durable Responses in Relapsed or Refractory Mantle Cell Lymphoma, Phase 2 Trial Shows

News

Calquence (acalabrutinib), a treatment for mantle cell lymphoma (MCL) patients who have failed at least one prior therapy, reduced tumor burden in four of five patients in a Phase 2 clinical ... Read more

December 14, 2018

Truxima Shows Safety, Efficacy Comparable to Rituxan in Advanced Follicular Lymphoma

News

Truxima (rituximab-abbs), a biosimilar to Rituxan (rituxumab), has similar safety and efficacy as the original product in patients with advanced follicular lymphoma after two years, results from a Phase 3 ... Read more

December 12, 2018

Follow-up Trial Results Reinforce Yescarta as Relapsed Non-Hodgkin’s Lymphoma Therapy

News

More than two years after receiving treatment with Yescarta (axicabtagene ciloleucel), 51% of non-Hodgkin’s lymphoma patients included in the ZUMA-1 Phase 1/2 clinical trial are still alive, and 39% are ... Read more

December 11, 2018December 11, 2018

Size Matters: Height May Heighten Risk Factor for Certain Cancers, Study Finds

News

Taller people have a higher risk of developing some types of cancer — including lymphoma — because they have a larger number of cells, according to a University of California, Riverside ... Read more

December 7, 2018

Generon Set to Begin Phase 1 Trial of A-319 in Patients With B-cell Cancers in China

News

China’s regulatory agency has approved the launch of Generon‘s Phase 1 clinical trial to test its immunotherapy candidate, A-319, in patients with acute lymphoblastic leukemia (ALL) and B-cell lymphoma. Approval of ... Read more

December 5, 2018

5F9-Rituxan Combo Eliminates Tumors in One-third of DLBCL, Follicular Lymphoma Patients

News

A combination of Forty Seven‘s macrophage checkpoint inhibitor Hu5F9-G4 and Rituxan (rituximab) is safe and completely eliminated tumors in one-third of non-Hodgkin’s lymphoma patients included in a Phase 1b trial. The trial, ... Read more

December 4, 2018

Truxima Becomes First Biosimilar to Rituxan Approved in US for Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration has approved Truxima (rituximab-abbs), a biosimilar to Rituxan (rituximab), for three CD20-positive non-Hodgkin’s lymphoma indications, Celltrion and Teva announced. The decision comes less than two months after the FDA’s Oncologic Drugs ... Read more

December 3, 2018

Poteligeo Approved in Europe for 2 Forms of Cutaneous T-cell Lymphoma

News

The European Commission approved the use of Poteligeo (mogamulizumab) for patients with mycosis fungoides or Sézary syndrome — the most common cutaneous T-cell lymphomas — who failed at least one prior systemic therapy. The approval follows ... Read more